Burleson & Co’s GSK GSK Stock Holding History

Burleson & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$12.9K	Hold	366	–	–	﹤0.01%	253
2022 Q3	$11K	Hold	366	–	–	﹤0.01%	276
2022 Q2	$20K	Hold	366	–	–	﹤0.01%	231
2022 Q1	$20K	Hold	366	–	–	﹤0.01%	230
2021 Q4	$20K	Hold	366	–	–	﹤0.01%	228
2021 Q3	$18K	Hold	366	–	–	﹤0.01%	232
2021 Q2	$18K	Hold	366	–	–	﹤0.01%	241
2021 Q1	$16K	Buy	+366	New	+$16.6K	﹤0.01%	235

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Burleson & Co's GSK Position: Q4 2022 in Review

Burleson & Co held its GSK (GSK) position steady in Q4 2022 at 366 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #253.

Burleson & Co first reported a position in GSK in Q1 2021 and has held it in 8 quarters since. The position peaked at $20K in Q2 2022. 814 funds tracked by Wall St. Rank hold GSK as of Q4 2022.

Burleson & Co held 366 shares of GSK worth $12.9K as of Q4 2022.
Burleson & Co left its GSK share count unchanged in Q4 2022.
GSK made up ﹤0.01% of Burleson & Co's portfolio in Q4 2022, its #253 holding.
Burleson & Co first reported a position in GSK in Q1 2021 and has held it in 8 quarters since.
Burleson & Co's GSK position peaked at $20K in Q2 2022.
814 funds tracked by Wall St. Rank held GSK as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.